Adimab
Adimab, a leading biotechnology company headquartered in the United States, was founded in 2007 and has since established itself as a pioneer in the field of antibody discovery and development. With a strong operational presence in key regions across the US and Europe, Adimab focuses on providing innovative solutions for therapeutic antibody generation, utilising its proprietary platform to streamline the discovery process. The company’s core offerings include a robust suite of services that enable partners to develop high-quality monoclonal antibodies efficiently. Adimab's unique approach combines advanced technology with a deep understanding of immunology, positioning it as a trusted partner for pharmaceutical and biotechnology firms. Notable achievements include collaborations with major industry players, solidifying its reputation as a leader in the antibody discovery landscape.
DitchCarbon Score
How does Adimab's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Adimab's score of 13 is lower than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Adimab's reported carbon emissions
Adimab, headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Adimab may still be in the early stages of developing its climate commitments or reporting framework. As of now, there are no emissions inherited from a parent company or cascaded from any corporate family relationships, indicating that Adimab operates independently in this regard. The absence of emissions data and reduction initiatives highlights a potential area for growth in their sustainability strategy, particularly as the industry increasingly prioritises climate action and transparency.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Adimab is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
